Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 214,097 shares of the biopharmaceutical company's stock after selling 72,448 shares during the period. Pictet Asset Management Holding SA owned about 0.19% of Regeneron Pharmaceuticals worth $152,508,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the stock. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Bank of America reissued an "underperform" rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $966.88.

Remove Ads

Regeneron Pharmaceuticals Stock Up 1.0 %

Shares of Regeneron Pharmaceuticals stock traded up $5.97 during trading hours on Wednesday, hitting $622.97. 439,878 shares of the company's stock traded hands, compared to its average volume of 676,921. Regeneron Pharmaceuticals, Inc. has a twelve month low of $607.72 and a twelve month high of $1,211.20. The company has a market cap of $68.11 billion, a PE ratio of 16.27, a PEG ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $681.52 and a 200-day simple moving average of $788.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.